GlassScriptPhysician profile
Christopher S Dziopala
NPI 1386030344
$10,825.11
in general payments reported to CMS, 2019-2025
21 companies · $2,514 in 2025
The $2,514 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,492 · 2022: $1,340 · 2023: $2,636 · 2024: $2,843 · 2025: $2,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,993.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,263.43 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,993.62 | 2021-2025 | |
| Abbott Laboratories | $1,281.98 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $686.48 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $648.60 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $505.44 | 2021-2025 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $398.71 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Biohaven Pharmaceuticals, INC. | $379.05 | 2021 | |
| Dexcom, INC. | $330.63 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Gilead Sciences, INC. | $246.88 | 2023-2025 | Epclusa |
| Exact Sciences Corporation | $184.64 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $144.93 | 2021-2025 | Repatha, Otezla, Repatha |
| Neurocrine Biosciences, INC. | $137.45 | 2024 | Ingrezza |
| Pfizer INC. | $117.01 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $111.45 | 2023 | Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.95 | 2023 | Quviviq |
| Rgh Enterprises LLC | $92.19 | 2025 | |
| Lucid Diagnostics INC. | $87.14 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.28 | 2022-2023 | |
| Insulet Corporation | $19.32 | 2024 | Omnipod |
| Merck Sharp & Dohme LLC | $13.93 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dziopala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.